Duality Advisers, LP Novo Cure LTD Transaction History

Duality Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	BUY	$40.29 - $82.51 $1.55 Million - $3.18 Million	38,540 Added 241.09%	54,526 $2.26 Million
Q1 2023 Jun 27, 2023	SELL	$56.44 - $118.81 $846,261 - $1.78 Million	-14,994 Reduced 48.4%	15,986 $961,000
Q4 2022 Feb 07, 2023	BUY	$63.98 - $85.37 $1.58 Million - $2.11 Million	24,683 Added 391.98%	30,980 $2.27 Million
Q3 2022 Nov 03, 2022	SELL	$67.99 - $89.57 $1.74 Million - $2.29 Million	-25,534 Reduced 80.22%	6,297 $478,000
Q2 2022 Aug 08, 2022	BUY	$56.6 - $89.9 $1.8 Million - $2.86 Million	31,831 New	31,831 $2.21 Million
Q1 2022 May 09, 2022	SELL	$60.15 - $84.52 $930,279 - $1.31 Million	-15,466 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$75.08 - $121.99 $48,651 - $79,049	-648 Reduced 4.02%	15,466 $1.16 Million
Q3 2021 Nov 08, 2021	BUY	$116.17 - $194.55 $1.16 Million - $1.95 Million	10,002 Added 163.65%	16,114 $1.87 Million
Q2 2021 Aug 09, 2021	BUY	$130.4 - $225.58 $153,741 - $265,958	1,179 Added 23.9%	6,112 $1.36 Million
Q1 2021 May 13, 2021	BUY	$124.11 - $190.17 $612,234 - $938,108	4,933 New	4,933 $652,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.